Hims & Hers Health Inc. Stock News

Upgrading Hims & Hers Health, Inc. to a speculative Buy after a 20% post-earnings selloff, given management's reaffirmed guidance and near-term demand for personalized compounded GLP-1s. I believe the FY 2025 revenue guidance of $725 million hinges almost entirely on continued sales of personalized compounded GLP-1s. Key HIMS stock risks include potential FDA or court bans on compounded GLP-1s ...

I remain bullish on Hims & Hers Health, viewing the recent price dip as a buying opportunity given its strong long-term prospects. Technological innovation and personalized care, including at-home lab testing and AI-driven recommendations, are transforming HIMS into a proactive health platform. Geographical expansion into Canada and Europe, along with strategic acquisitions, supports robust rev...

Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding product offerings, and direct-to-consumer model support my positive outlook on the stock. HIMS's focus on recurring subscription revenue and high customer retention rates enhances long-term financial ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo Nordisk ended the companies' partnership. The overall growth story continues regardless. Hims & Hers is launching new products and markets, while U.S. momentum has remained good in most other categories.

LOS ANGELES , Aug. 6, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) have opportunity to lead the securities fraud class action lawsuit.

Hims & Hers' NYSE: HIMS August price dip is an opportunity to buy, but investors shouldn't rush to get into this healthcare stock. Forces in play, including high short interest and tepid analyst involvement, are capping gains in 2025 and setting this market up for correction.

Growth stocks abound, and in every market environment, there are opportunities for every investor. If you have $1,000 to put to work in the stock market after accounting for all immediate and necessary expenses, there are plenty of compelling opportunities out there.

Hims & Hers Health Inc. (HIMS -12.42%) fell 12.36% to $55.52, with volume spiking to nearly 104 million shares--more than twice its three-month average. The stock now trades nearly 24% below its recent high, despite growing second-quarter revenue 73% year over year to $544.8 million.